`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_______________________
`
`PAR PHARMACEUTICAL, INC.,
`Petitioner
`
`v.
`
`SUMITOMO DAINIPPON PHARMA CO., LTD.,
`Patent Owner
`_______________________
`
`Case IPR2017-01292
`U.S. Patent No. 9,555,027
`_______________________
`
`JOINT REQUEST THAT AGREEMENT BE TREATED AS
`BUSINESS CONFIDENTIAL INFORMATION AND KEPT SEPARATE
`PURSUANT TO 35 U.S.C. § 317 AND 37 C.F.R. § 42.74
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`Pursuant to 35 U.S.C. § 317, 37 C.F.R. § 42.74, and the Board’s e-mail of
`
`July 27, 2017, Petitioner Par Pharmaceutical, Inc. (“Par”) and Patent Owner
`
`Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo”) jointly request that the
`
`parties’ agreement (Exhibit 2002)1 be treated as business confidential information
`
`and kept separate (i.e. under seal). This request is filed concurrently with the
`
`parties’ joint motion to terminate this proceeding.
`
`“At the request of a party to the proceeding, the agreement or understanding
`
`shall be treated as business confidential information, shall be kept separate from
`
`the file of the involved patents, and shall be made available only to Federal
`
`Government agencies on written request, or to any person on a showing of good
`
`cause.” 35 U.S.C. § 317(b); see also 37 C.F.R. § 42.74(c).
`
`The parties hereby request that their agreement (Ex. 2002) be treated as
`
`business confidential information, be kept separate from the file of patent (e.g., not
`
`accessible via PAIR or E2E), and be made available only to Federal Government
`
`agencies on written request, or to any person on a showing of good cause.
`
`
`
`
`
`
`1 This agreement was filed via E2E for “Parties and Board Only” to preserve
`
`confidentiality.
`
`1
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`Date: August 1, 2017
`
`
`
`
` By: /Daniel G. Brown/
`
`Daniel G. Brown (Reg. No. 54,005)
`Latham & Watkins LLP
`885 Third Avenue
`New York, NY 10022-4834
`Tel: (212) 906-1200
`Fax: (212) 751-4864
`daniel.brown@lw.com
`
`Lead Counsel for Petitioner Par
`Pharmaceutical, Inc.
`
`
`By: /Preston K. Ratliff II/
`Preston K. Ratliff II (Reg. No. 43,034)
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`Telephone: (212) 318-6055
`Facsimile: (212) 230-7742
`PH-Par-SunovionIPR@paulhastings.com
`
`Lead Counsel for Patent Owner
`Sumitomo Dainippon Pharma Co., Ltd.
`
`2
`
`
`
`
`
`IPR2017-01292
`U.S. Patent No. 9,555,027
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), I certify that on this 1st day of August,
`
`2017, a copy of Joint Request That Agreement Be Treated As Business
`
`Confidential Information And Kept Separate Pursuant To 35 U.S.C. § 317
`
`And 37 C.F.R. § 42.74 was served by electronic mail on Petitioner’s lead and
`
`backup counsel at the following email addresses:
`
`daniel.brown@lw.com
`jonathan.strang@lw.com
`
`
`
`
`
`
`
`
`
`By: /Preston K. Ratliff II/
`Preston K. Ratliff II (Reg. No. 43,034)
`Paul Hastings LLP
`200 Park Avenue
`New York, NY 10166
`Telephone: (212) 318-6055
`Facsimile: (212) 230-7742
`PH-Par-SunovionIPR@paulhastings.com
`
`Lead Counsel for Patent Owner
`Sumitomo Dainippon Pharma Co., Ltd.
`
`